SEC Comment Letter for Theriva Biologics, Inc. (TOVX) (CIK 0000894158) (TOVX) — May 31, 2012

Theriva Biologics, Inc. (TOVX) (CIK 0000894158)
Date: May 31, 2012 · CIK: 0000894158 · Accession: 0000000000-12-028122

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-12584

Date

May 31, 2012

Author

/s/ Jim B. Rosenberg

Form

UPLOAD

Company

Theriva Biologics, Inc. (TOVX) (CIK 0000894158)

Letter

May 31, 2012 Via E -mail Mr. C. Evan Ballantyne Chief Financial Officer Synthetic Biologics, Inc. 3985 Research P ark Drive Suite 200 Ann Arbor, MI 48108

Re: Synthetic Biologic , Inc. Item 4.0 2 Form 8 -K Filed May 3, 2012 File No. 001-12584

Dear Mr. Ballantyne :

We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are re sponsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing include s the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,
/s/ Jim B. Rosenberg

Show Raw Text

May 31, 2012

Via E -mail
Mr. C. Evan Ballantyne
Chief Financial Officer
Synthetic Biologics, Inc.
3985 Research P ark Drive
Suite 200
Ann Arbor, MI  48108

Re: Synthetic Biologic , Inc.
Item 4.0 2 Form 8 -K
Filed  May 3, 2012
  File No. 001-12584

Dear Mr.  Ballantyne :

We have completed our review of your filing .  We remind you that our comments or
changes to disclosure in response to our comments do not foreclose the Commission from taking
any action with respect to the company or the filing  and the company may not assert staff
comments as a defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United States.  We urge all persons who are re sponsible for the
accuracy and adequacy of the disclosure in the filing  to be certain that the filing  include s the
information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

 /s/ Jim B. Rosenberg

        Jim B. Rosenberg
        Senior Assis tant Chief Accountant

SecProbe.io